Regulatory compliance – Page 62

Uncontrolled document revisions during routine operations – ALCOA+ gap analysis

Managing Uncontrolled Document Revisions During Routine Operations: An ALCOA+ Gap Analysis Playbook The pharmaceutical industry is continually challenged by the need to maintain stringent documentation integrity while managing the dynamic…

Team unprepared for interviews during remediation tracking – CAPA closure verification

How to Prepare Teams for Interviews During Remediation Tracking to Ensure CAPA Closure Verification When preparing for regulatory inspections, one critical area often overlooked is team readiness for interviews related…

Backdated documentation detected during deviation investigation – inspection citation risk and mitigation

Mitigating Inspection Risks from Backdated Documentation During Deviation Investigations In the pharmaceutical manufacturing landscape, the integrity of documentation is paramount. The presence of backdated documentation during a deviation investigation poses…

Inspection readiness untested during WHO audit – CAPA closure verification

Playbook for Ensuring Inspection Readiness in Light of WHO Audit Findings As pharmaceutical manufacturing and quality professionals, we face an ongoing challenge in maintaining consistent compliance with regulatory standards. Specifically,…

Uncontrolled document revisions during audit trail review – evidence pack inspectors expect

Managing Uncontrolled Document Revisions During Audit Trail Review in Pharma In the pharmaceutical manufacturing landscape, the integrity of documentation is paramount. Uncontrolled document revisions during audit trail review can lead…

CAPA follow-up weak during post-inspection response – question-and-answer handling techniques

Enhancing CAPA Follow-Up Post-Inspection Response: A Practical Playbook In the regulated pharmaceutical industry, handling deficiencies identified during inspections necessitates an efficient CAPA (Corrective and Preventive Action) process. When responses to…

Illegible entries in controlled records during audit trail review – inspection citation risk and mitigation

Mitigating Risks from Illegible Entries in Controlled Records During Audit Trail Review Addressing illegible entries in controlled records is critical for pharmaceutical operations, especially during audit trail reviews. Non-compliance with…

Inspection readiness untested during FDA/EMA inspection – preventing escalation to warning letter

Ensuring Inspection Readiness to Prevent Escalations During FDA/EMA Inspections In today’s highly regulated pharmaceutical environment, maintaining inspection readiness is crucial. A lack of proper protocols can lead to serious consequences,…

Illegible entries in controlled records during deviation investigation – GDP remediation CAPA

Managing Illegible Entries in Controlled Records during Deviation Investigations Illegible entries in controlled records can significantly impact a pharmaceutical organization’s compliance with Good Documentation Practices (GDP) and data integrity standards,…

Tag: Regulatory compliance